Opinion|Videos|July 29, 2024
Expert Perspectives in Navigating Treatment Strategies with CDK4/6 Inhibitors in HR+ Breast Cancer
A panel of experts offer perspectives in navigating treatment strategies with CDK4/6 inhibitors.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Treatment options post progression on CDK4/6i + ET
- What is your overall perception on the class of oral SERDs? How will they continue to impact the treatment landscape?
- What are your perceptions on efficacy and safety data? What has your experience been in practice with:
- Elacestrant
ASCO 2024 #1071 : Real-world (RW) elacestrant use patterns and therapeutic outcomes.ASCO 2024 #1064 : Elacestrant plus abemaciclib Preliminary data from ELECTRAASCO 2024 #1069 : Elacestrant in various combinations: Preliminary data from ELEVATEBardia Cancer Res 2023 : GS3-01 EMERALD phase 3 trial of elacestrant vs endocrine therapy: Updated results by duration of prior CDK4/6i in metastatic setting
- Elacestrant
Advertisement
Related to this article
The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.
The FDA approved imlunestrant/abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after progression on endocrine therapy.
Japan approved T-DXd plus pertuzumab for HER2-positive disease and Dato-DXd for triple-negative disease in first-line metastatic breast cancer.
Obesity may increase breast cancer risk partly by removing a natural defense.
Camizestrant plus palbociclib did not significantly improve progression-free survival vs anastrozole plus palbociclib in the first-line SERENA-4 trial.
Advertisement
Advertisement
Trending on OncLive
1
CLL Treatment Individualization Prompts Changes in Patient Evaluation and Care
2
Japan Approves Subcutaneous Pembrolizumab for All Approved Pembrolizumab Indications
3
FDA Grants Fast Track Designation to LYT-200 in R/R High-Risk MDS
4
Integrating Bispecific Antibodies Into Frontline Therapy for Newly Diagnosed Multiple Myeloma
5